Turning cold tumors hot: from molecular mechanisms to clinical applications
J Zhang, D Huang, PE Saw, E Song - Trends in immunology, 2022 - cell.com
Immune checkpoint blockade (ICB) therapies have achieved clinical benefit, but most
'immune-cold'solid tumors are not responsive. The diversity of immune evasion mechanisms …
'immune-cold'solid tumors are not responsive. The diversity of immune evasion mechanisms …
Intratumoral heterogeneity in cancer progression and response to immunotherapy
Most (if not all) tumors emerge and progress under a strong evolutionary pressure imposed
by trophic, metabolic, immunological, and therapeutic factors. The relative impact of these …
by trophic, metabolic, immunological, and therapeutic factors. The relative impact of these …
Mismatch repair deficiency is not sufficient to elicit tumor immunogenicity
PMK Westcott, F Muyas, H Hauck, OC Smith… - Nature Genetics, 2023 - nature.com
DNA mismatch repair deficiency (MMRd) is associated with a high tumor mutational burden
(TMB) and sensitivity to immune checkpoint blockade (ICB) therapy. Nevertheless, most …
(TMB) and sensitivity to immune checkpoint blockade (ICB) therapy. Nevertheless, most …
Tumor mutational burden as a predictive biomarker in solid tumors
Tumor mutational burden (TMB), defined as the number of somatic mutations per megabase
of interrogated genomic sequence, varies across malignancies. Panel sequencing–based …
of interrogated genomic sequence, varies across malignancies. Panel sequencing–based …
The updated landscape of tumor microenvironment and drug repurposing
Accumulating evidence shows that cellular and acellular components in tumor
microenvironment (TME) can reprogram tumor initiation, growth, invasion, metastasis, and …
microenvironment (TME) can reprogram tumor initiation, growth, invasion, metastasis, and …
Improved prediction of immune checkpoint blockade efficacy across multiple cancer types
Only a fraction of patients with cancer respond to immune checkpoint blockade (ICB)
treatment, but current decision-making procedures have limited accuracy. In this study, we …
treatment, but current decision-making procedures have limited accuracy. In this study, we …
Mutational signatures: emerging concepts, caveats and clinical applications
Whole-genome sequencing has brought the cancer genomics community into new territory.
Thanks to the sheer power provided by the thousands of mutations present in each patient's …
Thanks to the sheer power provided by the thousands of mutations present in each patient's …
Stem-like CD8 T cells mediate response of adoptive cell immunotherapy against human cancer
Adoptive T cell therapy (ACT) using ex vivo–expanded autologous tumor-infiltrating
lymphocytes (TILs) can mediate complete regression of certain human cancers. The impact …
lymphocytes (TILs) can mediate complete regression of certain human cancers. The impact …
Beyond immune checkpoint blockade: emerging immunological strategies
The success of checkpoint inhibitors has accelerated the clinical implementation of a vast
mosaic of single agents and combination immunotherapies. However, the lack of clinical …
mosaic of single agents and combination immunotherapies. However, the lack of clinical …
Neoadjuvant immunotherapy leads to pathological responses in MMR-proficient and MMR-deficient early-stage colon cancers
M Chalabi, LF Fanchi, KK Dijkstra, JG Van den Berg… - Nature medicine, 2020 - nature.com
Abstract PD-1 plus CTLA-4 blockade is highly effective in advanced-stage, mismatch repair
(MMR)-deficient (dMMR) colorectal cancers, yet not in MMR-proficient (pMMR) tumors. We …
(MMR)-deficient (dMMR) colorectal cancers, yet not in MMR-proficient (pMMR) tumors. We …